Severe early-childhood-onset retinal dystrophy
MONDO:0009549Severe early childhood onset retinal dystrophy (SECORD) is an inherited retinal dystrophy, characterized by a severe congenital night blindness, progressive retinal dystrophy and nystagmus. Best corrected visual acuity can reach 0.3 in the first decade of life and can pertain well into the second decade of life. Blindness is often complete by the age of 30 years. An overlap with Leber congenital amaurosis (LCA) occurs when patients are characterized by their visual acuity and panretinal dystrophy.
Also known as: EOSRD, SECORD, Stargardt disease type 1, early-onset severe retinal dystrophy, STGD1, Stargardt disease 1, Stgd, fundus flavimaculatus
35 clinical trials for this condition and its sub-types, 8 tagged with Severe early-childhood-onset retinal dystrophy itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New hope for rare eye disease: drug trial targets vision loss
Disease control OngoingThis study tests a drug called tinlarebant in 60 people with Stargardt disease, a genetic condition that causes vision loss. The goal is to see if the drug can slow damage to the retina and preserve eyesight. Participants take the drug or a placebo, and researchers measure change…
Phase 2/3 • Sponsor: Belite Bio, Inc • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New app could spot eye disease from your couch
Diagnosis By invitation onlyThis study is testing a smartphone app called NEDS EyeCTester to see if it can help detect active eye disease early in people with conditions like optic nerve or macular disease. About 100 participants will use the app at home, and researchers will compare the results to standard…
Sponsor: Neuro-Eye Diagnostic Systems, LLC • Aim: Diagnosis
Last updated Jun 27, 2026 12:06 UTC
-
Scientists track rare eye disease to prepare for future treatments
Knowledge-focused OngoingThis study follows 68 people aged 12 and older who have ABCA4 gene mutations, which can cause vision loss from diseases like Stargardt disease. Over 10 years, researchers will collect blood and skin samples and perform detailed eye exams to understand how the disease progresses. …
Sponsor: National Eye Institute (NEI) • Aim: Knowledge-focused
Last updated Sep 03, 2026 00:00 UTC
-
Stem cell eye therapy: 5-Year safety watch begins
Knowledge-focused By invitation onlyThis study follows people who received a stem cell treatment for macular degeneration to see if any late side effects appear more than 5 years later. Participants fill out a yearly questionnaire about eye problems, infections, immune disorders, cancer, or other health changes. Th…
Phase 1/2 • Sponsor: Astellas Institute for Regenerative Medicine • Aim: Knowledge-focused
Last updated Jul 15, 2026 00:00 UTC